Loading...
Loading...
- Nascent Biotech Inc NBIO has announced the publication of promising in-vitro study results from its pritumumab (PTB) research collaboration with Syracuse University, validating the potential for PTB for COVID-19 symptoms.
- The data showed that pritumumab successfully blocked 80% of viral entry into cells. Now PTB will be advanced to laboratory-based animal studies.
- Nascent is currently developing methods to treat viral infections along with a traditional vaccine platform.
- Besides, Nascent recently opened its Phase 1 trial for Brain Cancer at Hoag Family Cancer Institute and Pickup Family Neurosciences Institute Presbyterian, and additional updates are anticipated soon.
- Price Action: NBIO gained 60% at $0.14 in market trading hours on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in